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Approximately 256,000 cases of malignant brain and nervous system cancer were diag-
nosed worldwide during 2012 and 189,000 deaths, with this burden falling more heavily in
the developed world. Problematically, research describing the psychosocial needs of peo-
ple with brain tumors and their carers and the development and evaluation of intervention
models has lagged behind that of more common cancers. This may relate, at least in part,
to poor survival outcomes and high morbidity associated with this illness, and stigma about
this disease. The evidence base for the benefits of psychosocial care in oncology has sup-
ported the production of clinical practice guidelines across the globe over the past decade,
with a recent mandate to integrate the psychosocial domain and measurement of distress
into routine care. Clinical care guidelines for people with brain tumors have emerged, with
a building focus on psychosocial and survivorship care. However, researchers will need
to work intensively with health care providers to ensure future practice is evidence-based
and able to be implemented across both acute and community settings and likely within
existing resources.
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THE HEALTH BURDEN OF BRAIN TUMORS
It was estimated that there were approximately 256,000 cases of
malignant brain and nervous system cancer (ICD-10 codes C70-
C72) diagnosed worldwide during 2012 (age standardized rate of
3.4/100,000) and 189,000 deaths (2.5/100,000) (1). The incidence
rate of cancers of the brain and nervous system was almost double
in more developed countries compared to less developed coun-
tries (5.1/100,000 and 3.0/100,000, respectively) and was higher for
males (3.9/100,000) than females (3.0/100,000). Five-year preva-
lence was 343,000 in total. This disease carries a heavy psychosocial
burden (2, 3), and often occurs at the age of middle adult life with
41% of brain tumor patients globally aged younger than 50 years
(median age range of 55–59 years) (1). The middle adult life stage
is a time of potential generativity (4), such that the loss of func-
tion and loss of life from an individual, family, community and
economic perspective is substantial.
Patients with brain tumor suffer from a high rate of psy-
chiatric and psychological disorders that are quite specific and
distinct from other areas of psycho-oncology. In fact, unlike sys-
temic effects of other tumors and treatment, brain tumors have a
direct effect on brain functioning affecting cognition, mood, and
personality, with profound changes in mood and cognition and
impairments in several dimensions of functioning (5) and quality
of life (6–8). A series of data have been collected regarding the
effects of primary brain tumors on individual psychological func-
tioning and psychosocial dimensions. The most significant and
common disorders regard cognitive dysfunction, affecting about
70% of the patients. Disorders of memory, attention, and con-
centration have been described, with a tendency to worsen as the
lesion increases or invades CNS areas. Acute confusional states (i.e.,
delirium) are also common neurocognitive complications of brain
tumors. Clinically, some dysfunctions and symptoms are described
in terms of “specific” syndromes, such as frontal lobe syndromes
(caused by tumors in the frontal lobe) with several manifestations,
including agitation, behavioral disruption and emotional lability
(e.g., orbitofrontal disinhibited syndrome), psychomotor slowness
and apathy (e.g., mesial frontal apathetic syndrome), and disorders
of the executive functions, perseveration, and psychomotor slow-
ing (e.g.,dorsolateral prefrontal dysexecutive syndrome); temporal
lobe syndrome, with impairment of verbal and non-verbal mem-
ory and seizures (9). A further major challenge of these disorders,
and in neuro-oncology in general, is represented by a frequently
undetected and under-recognized possible effect of psychiatric dis-
orders, mainly cognitive impairment, in reducing patients’ mental
capacity with problems in providing informed consent (10, 11).
Further syndromes related to brain tumors that have to be
taken into account regard mood disorders, including depres-
sion and mania (25–30%), anxiety disorders (15–70%), changes
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in personality traits (sometimes subtle in the beginning phase,
sometimes abrupt and dramatic), and psychotic disorders (12).
Significant neuropsychiatric disorders may be the consequence
of intervention, including surgery, radiotherapy, and, especially,
drugs (e.g., psychotic syndromes and behavioral disorders sec-
ondary to corticosteroids) (13). Evaluation of patients’ symptoms,
by conducting a careful neuropsychological and psychiatric assess-
ment, is mandatory in clinical settings in order to provide the most
proper psychopharmacological (e.g., antidepressants, anticonvul-
sants, antipsychotics) and psychotherapeutic intervention. With
regard to the latter, the need for specific educational, supportive,
and psychosocially oriented intervention for the patients’ families
has also been repeatedly underlined (14–16). However, a recent
review concluded that the research to date on the complex needs
of brain tumor patients and how to best help them is limited in
scope, with little attention to how to provide supportive care (17).
This gap also extends to survivorship care and planning.
CANCER SURVIVORSHIP, STIGMA, AND SOCIAL
REPRESENTATIONS OF ILLNESS
The National Cancer Institute defines cancer survivorship as focus-
ing on the health and life of a person with cancer from diagnosis
and treatment until end of life, including the physical, psychoso-
cial, and economic issues of cancer through the balance of his or
her life. Within this definition, the experience of family members,
friends, and caregivers are also considered relevant (18). The lan-
guage applied within this discourse is intended to be empowering,
signaling a shift from cancer “victim” terminology to a survivor
framework. However, not all people who have had cancer perceive
themselves to be a cancer survivor (19), and some suggest that
this label marginalizes those who have a poor prognosis or high
cancer-related morbidities (20, 21).
Stigma is when a person is seen by society as tainted, damaged,
or less valuable as a result of an attribute or characteristic (22).
Stigmatizing marks can be linked to appearance (e.g., physical
appearance or overt behavioral differences) or group membership
(e.g., race or religion), and is relationship and context specific (23).
In health, stigma is reported to be higher for illnesses that are linked
to modifiable lifestyle factors (e.g., smoking, drug or alcohol abuse,
sexual activity), disfigurement or outward signs of illness, or a
painful death (24). For example, cervical cancer has been reported
as stigmatizing on the basis of its relationship with human papil-
loma virus and from this inferred sexual activity (25). People with
lung cancer report feeling stigmatized based on the connection
between smoking and lung cancer, as well as the high morbidity
and mortality of the disease (24). The changes in facial appear-
ance that may accompany head and neck cancer have been linked
to stigma in this patient group (26) and patients with Parkinson’s
disease who have facial masking are more negatively judged that
those with normal expressivity (27). Finally, epilepsy is reported
as being globally one of the most stigmatizing health conditions,
linked to perceptions of it as being unpredictable, unattractive and
violent, and representative of mental illness (28, 29).
Hence, although it is suggested that stigma about cancer in
general has declined over the past four decades (30), some patient
groups still experience stigma. People with brain tumors may expe-
rience stigma as a result of the cognitive, behavioral, and physical
changes that may result from the tumor or treatment, as well as
fears about a cancer that for some may have a poor outcome.
Brain tumor patients therefore may experience social stigma as a
result of their cognitive and neurological symptoms, and this may
deepen these patients’ sense of social isolation and discrimination
(31). Within this, the perception of a brain tumor as “mind-body”
illness may be stigmatizing for both the patient and their fam-
ily. In some cultures, this effect is worsened by lay beliefs about
the causes of illness. For example, in a qualitative study in Ban-
galore, people with glioblastoma reported that their illness was a
punishment from God for previous sins, or Karma, or a result of
black magic (32). Palese et al. proposed that patients with frontal
lobe neoplasms may be more at risk of stigma and having their
problems underestimated by nurses than those with other cerebral
neoplasms (33). However, findings were mixed with a tendency for
nurses to overestimate problems more common. It is perhaps sur-
prising, however, how little research has been undertaken about
health-related stigma in brain tumor patients and how this affects
their lives and their access to and utilization of health care services.
In this regard, stigma is connected to poorer outcomes in
life across the domains of health, education, and access to social
resources and in the case of people with stigmatized health con-
ditions contributes to higher subjective distress about their illness
(34). It is well accepted that there is a stigma around mental illness
in Western culture (35, 36), and it has been further suggested that
this stigma is also a barrier to cancer patients seeking and obtain-
ing help for the distress associated with cancer (37). This means
that patients who have a stigmatizing cancer may be doubly dis-
advantaged: more distress and less help. In addition, a broader
health sector outcome of stigma [that has been well discussed in
lung cancer (38)] is that stigmatized conditions may be under-
funded for research and services. Consistent with this, in 2004 in
the House of Commons John Brecow, the Chair of the brain tumor
All Party Parliamentary Group made the point that “the issue
of brain tumors is under-debated, under-reported, and under-
funded. In this Parliament, the issue has attracted minimal – dare
I say it, derisory – attention.” In this context, quality frameworks
for health service delivery can play a crucial role in evening the
playing field.
GUIDELINES AND QUALITY STANDARDS FOR
PSYCHOSOCIAL CARE
Psycho-oncology and psychosocial oncology are, relative to bio-
medical treatments for cancer, a recent development in modern
cancer care. Surgical treatment was the forerunner of cancer treat-
ment, an approach that became more widely possible in the nine-
teenth century with the development of anesthesia and the first
successful brain tumor surgical removal reported in 1879 (39). At
the beginning of the twentieth century radiation therapy emerged
as a cancer treatment (40), followed in 1940s by chemotherapy
(41). By contrast, although the psychosocial care of people with
cancer arguably does not hinge on technological advancement,
the emergence of this field followed decades later, perhaps best
heralded by the formation in 1984 of the International Psycho-
Oncology Society (IPOS). IPOS led the mission to improve the
care of cancer patients and their families globally by promoting
the science of psycho-social and behavioral oncology (42) and the
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publication in 1989 of the first textbook in the field (43). A more
recent milestone was the introduction of quality standards for psy-
chosocial care by IPOS in 2010 (44). Parallel to these developments
was the emergence of the cancer survivorship movement, with the
formation in 1986 of the National Coalition for Cancer Survivor-
ship (NCCS). The NCCS promoted itself as an advocacy collective
for cancer survivors followed a decade later by the National Can-
cer Institute Office of Cancer Survivorship with the mission to
promote cancer survivorship programs and research.
Over the past decade, a number of countries have developed
generic clinical practice guidelines for the psychosocial care of
adults with cancer. In Australia, these were first developed for
women with breast cancer, and then later revised in 2003 to cover
all adults with cancer (45). Similar work followed after in Canada,
United Kingdom, and European Union (46–48). However, while
clinical practice guidelines provide an evidence-based reference
point to guide care, they are limited by the a priori review scope
and are of less direct application in a field where evidence is scant.
This means that the depth of direction and advice to addressing
the specific and specialized needs of brain tumor patients and
their families in such guidelines is limited. As well, the develop-
ment and dissemination of guidelines do not necessarily change
practice (49). Further actions to improve practice in psychosocial
care included the Institutes of Medicine 2007 report “Cancer Care
for the Whole Patient: Meeting Psychosocial Health Needs” with
the major recommendation that “quality cancer care today must
integrate the psychosocial domain into routine cancer treatment”
(50). In 2010, IPOS published a new international quality standard
supporting the integration of psychosocial care and proposing a
distress screening and management be included in routine care by
placing it as one of the six Vital Signs (44). These standards have
now been widely endorsed internationally.
A number of medically focused guidelines specific to brain
tumors have been developed in Australia, United Kingdom, and
North America (34, 51–55). While broadly speaking these tend
to focus on the medical management of diagnosis and treat-
ment, the Australian Clinical Practice Guidelines for the Man-
agement of Adult Gliomas: astrocytomas and oligodendrogliomas
addresses the cognitive and personality changes that can occur in
these patients and provides recommendations for identification
and management of psychological disorders, cognitive problems
and personality, and other changes related to the tumor or its
treatment (52). This includes advice about the need for early
identification of psychological distress and referral for psychoso-
cial treatment for those with or at risk of significant distress.
Neuro-rehabilitation within a multi-disciplinary care model is also
advised. This approach of psychological assessment and support as
an integral part of the management of patients with brain tumor
is also advised elsewhere with referral to neuropsychology and
neuropsychiatry services advised for patients who require special-
ist intervention for cognitive, emotional, or behavioral problems
(54). Nursing clinical practice guidelines developed by the Amer-
ican Brain Tumor Association and the American Association of
Neuroscience Nurses also specifically address nursing assessment
for a range of problems including fatigue, distress, and body image
with referral for rehabilitation (51). Notably, these guidelines also
discuss survivorship issues including the need for support for
caregivers. Finally, the National Comprehensive Cancer Network
survivorship guidelines do note that that cognitive impairment is
prominent in survivors of primary central nervous system cancers
or people with brain metastases; however, acknowledge that there
is limited evidence to date to guide management of this condition,
especially for cancers other than breast (53).
Despite these encouraging developments there are barriers
to the implementation of psychosocial and survivorship care in
oncology settings, which include the continued dominance of
biomedical care models; gaps in knowledge about research transla-
tion; diminishing health budgets in the face of escalating costs; and
individual and community attitudes to illness and help seeking (44,
56, 57). In brief, while quality standards and guidelines provide
guidance for key characteristics of good oncology care, opera-
tionalizing these in the clinical or community setting presents its
own challenges. Care models that are practically translatable are
needed.
STEPPED CARE MODELS
One approach to this problem has been to develop care frame-
works that show how services articulate across levels of distress
and that focus on delivering the most in-depth (and expensive)
services to those who need them most. A tiered approach tailors
services to need through screening, triage and referral to different
levels of intervention appropriate to each patient (58). At the most
basic level, psychosocial care would include cancer-related infor-
mation and brief support from a health care professional in the
treatment team; cancer-related telephone helpline and other infor-
mation focused interventions. Those with higher levels of distress
that require more specific psychological interventions, including
people with pre-existing vulnerabilities or complex problems (e.g.,
neurocognitive deficits) are referred to more intensive, specialized,
or multidisciplinary approaches. Transition to more specialized
and in-depth levels of care is guided by standardized distress
screening, as per the best practice internationally, and interview
assessment by the treating health professional. A stepped care
approach differs in that a decision analytic approach is applied
with systematic identification of high need patients followed by
an integrated treatment program where care is stepped up pro-
gressively until the problem is resolved (59). These approaches
have not yet to our knowledge been applied to people with brain
tumors; however, the articulation of a tiered or stepped care model
for this patient group that incorporates specific needs of brain
tumor patients seems warranted.
All such models are predicated on applying screening for dis-
tress to guide referral to the appropriate level of care, or stepping
up of care as needed. The distress thermometer is an ultra-brief
screening measure that has been widely validated globally across
cultures and tumor sites and found to be a reliable first-line screen-
ing tool for detecting psychological distress in cancer patients (60,
61). This measure includes a problem checklist and a single item
asking the patient how much distress they have been experienc-
ing in the past week including the current day on a scale of 0, no
distress to 10, extreme distress (62, 63). Although the most com-
monly recommended cut-off for this scale is >4, in the case of
people with intracranial tumors a cut-off of>6 has been reported
as having optimal sensitivity for detecting distress (64). A key
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FIGURE 1 | Overview of challenges and strategies for integrating psychosocial care into neuro-oncology.
advantage of the distress thermometer is that it is short and easy to
administer and score thus making it ideal for translation into acute
settings. Other researchers have found the two item Patient Health
Questionnaire-2 (65) to have acceptable psychometric properties
for detecting moderate to severe psychological distress in brain
tumor patients (66). In contrast, Rooney et al. (67) have recom-
mended longer scales and in particular the Hospital Anxiety and
Depression Scale (68) and Patient Health Questionnaire-9 (69)
for detecting major depressive disorder in well-functioning glioma
patients as a preceding step to more in-depth clinical assessment
(67). The important question of how screening for neurological
and cognitive impairment can be undertaken in these patients
alongside distress screening, particularly in settings where special-
ist staff may not be easily accessed, is a key future question for both
researchers and health care providers.
CONCLUSION
There is a need for a comprehensive model of survivorship care for
people affected by brain tumor and their families and this should
be a priority for neuro-oncology (Figure 1). Given the more
advanced stage of development of such care in other cancers, there
is a platform of existing knowledge upon which neuro-oncology
practitioners may build. This includes screening for distress with
referral as needed into stepped and evidenced-based care models.
However, although clinical care guidelines specifically for people
with brain tumors are emerging, there is a scarcity of intervention
research in the field. There is a clear need for a strategic focus on
knowledge generation around survivorship for this patient group.
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